Two cases receiving retreatment with 12 weeks of glecaprevir and pibrentasvir for HCV genotype 2 infection who failed prior glecaprevir and pibrentasvir therapy

Abstract

We report two cases that achieved sustained virological response (SVR) upon 12 weeks of glecaprevir (GLE) and pibrentasvir (PIB) for HCV genotype 2 infection after failing prior GLE/PIB. Case 1 was a 65-year-old man without cirrhosis. His HCV RNA relapsed after the end of GLE/PIB therapy for 8 weeks; subsequently, he received retreatment with 12 weeks of GLE/PIB therapy. Although he harbored HCV NS5A-L28F+L31M+C92S at pre-GLE/PIB retreatment, he achieved SVR. Case 2 was a 51-year-old woman with cirrhosis. She discontinued GLE/PIB therapy at 3 days owing to pruritus in another hospital. Subsequently, she completed 12 weeks of GLE/PIB therapy combined with nalfurafine hydrochloride without any adverse events in our hospital, and achieved SVR. These findings suggest that prolongation of the treatment period to 12 weeks might have contributed to SVR, even if they received retreatment with the same drugs.